GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B6902 AS 19Summary: Potent 5-HT7 agonist -
B6922 PSB 1115Summary: human A2B adenosine receptor antagonist -
B6923 PSB 10 hydrochlorideSummary: human adenosine A3 receptor antagonist -
B6924 PSB 11 hydrochlorideSummary: human adenosine A3 receptor antagonist -
B6926 PSB 36Summary: A1 adenosine receptor antagonist -
B6930 CinalukastSummary: CysLT1 (LTD4) leukotriene receptor antagonist -
B6946 RS 102895 hydrochlorideSummary: CCR2-selective chemokine receptor antagonist -
B6957 NTNCB hydrochlorideSummary: NPY Y5 antagonist -
B6958 WAY 629 hydrochlorideSummary: 5-HT2C agonist -
B6965 SR 27897Summary: CCK1 receptor antagonist

